GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Short Interest

Q BioMed (Q BioMed) Short Interest


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Q BioMed's Short Interest

For the Biotechnology subindustry, Q BioMed's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Short Interest distribution charts can be found below:

* The bar in red indicates where Q BioMed's Short Interest falls into.


Q BioMed (Q BioMed) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Short Interest
Comparable Companies
RGMP CALA PPCB RSPI RGIN RGTPQ HGEN MYMX ATRX NMTRQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Website
https://www.qbiomed.com
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1